Use of Vasopressin Following the Fontan Operation
Study Details
Study Description
Brief Summary
The purpose of this study is to determine whether Vasopressin following the Fontan operation will decrease chest tube output and duration.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
A pilot and subsequently a multicenter, randomized, double blinded clinical trial to evaluate the use of vasopressin following the Fontan operation.
Phase one of the study will be a single center pilot study and will be conducted at Advocate Children's Hospital, Oak Lawn IL. This will be a randomized and double blinded. Ten patients will be enrolled with five patients as control group and five receiving Vasopressin. Vasopressin levels will be obtained just prior to initiation of Vasopressin and 48 hours later in the pilot study. Safety and effect size will be evaluated after this pilot study.
The multicenter study will be phase two and will be conducted in the cardiac operating rooms and cardiac intensive care unit (CVICU) of 7 pediatric cardiovascular programs in the United States. The investigators will be enrolling 12 subjects undergoing the Fontan operation from each participating institution. Six patients will be randomly assigned to receive Vasopressin while six will receive placebo.
A total of 84 patients undergoing the Fontan operation will be included in the study and randomized to one of the two treatment groups.
Group 1 will include 42 subjects who will receive the treatment drug (Vasopressin) for 48 hours following the Fontan operation. Group 2 will include 42 subjects who will receive placebo (normal saline) and will serve as a control group.
Drug administration protocol:
Vasopressin at a dose of 0.4 mU/kg/min will be started on subjects in the study group while coming off cardiopulmonary bypass. The dose of Vasopressin will not be titrated. Study drug drip will infuse for 48 hours after which will be discontinued.
The placebo group will be receiving normal saline at the same rate of the vasopressin group. The treating physician will be blinded.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Vasopressin Vasopressin at 0.4mU/kg/min |
Drug: Vasopressin
Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Other Names:
|
| Placebo Comparator: Normal saline Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation. |
Drug: Normal Saline
Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Chest tube drainage [From post operative day 0 through study completion, an average of 1 month]
chest tube drainage in ml/kg/day until the day the chest tube is removed
Secondary Outcome Measures
- Length of hospital stay [From the day of the surgery (post operative day 0) through study completion, an average of 1 month]
Duration the patient remains in the hospital in days until the day of discharge home
Eligibility Criteria
Criteria
Inclusion Criteria:
- Subjects between 1.5-7 years old undergoing Fontan operation.
Exclusion Criteria:
-
Patients with a planned fenestrated Fontan.
-
Patients undergoing revision surgery for failing Fontan.
-
Evidence of renal insufficiency prior to surgery defined by creatinine >1 mg/dl.
-
Planned arch reconstruction at the time of the Fontan procedure
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Advocate Children's Hospital | Oak Lawn | Illinois | United States | 60453 |
Sponsors and Collaborators
- Advocate Health Care
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HRP-530